Stock Events

Mirum Pharmaceuticals 

$24.42
23
+$0.25+1.03% Tuesday 20:00

Statistics

Day High
25.01
Day Low
24.3
52W High
35.56
52W Low
23.29
Volume
423,071
Avg. Volume
429,724
Mkt Cap
1.15B
P/E Ratio
-6.11
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-1.94
-1.37
-0.81
-0.24
Expected EPS
-0.44
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MIRM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap101.91B
Vertex Pharmaceuticals is involved in developing treatments for liver diseases, directly competing with Mirum's focus on rare liver conditions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap18.19B
Alnylam Pharmaceuticals works on RNAi therapeutics for a variety of conditions, including liver diseases, competing in the same therapeutic space as Mirum.
Gilead Sciences
GILD
Mkt Cap83.12B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, positioning it as a competitor in the hepatology market.
Abbvie
ABBV
Mkt Cap294.65B
AbbVie has a diverse drug portfolio that includes treatments for liver diseases, making it a competitor in the same market as Mirum.
Pfizer
PFE
Mkt Cap147.23B
Pfizer has a wide range of pharmaceutical products, including treatments for liver conditions, competing with Mirum Pharmaceuticals.
Novartis
NVS
Mkt Cap206.64B
Novartis AG engages in the research, development, and marketing of healthcare products, including liver disease treatments, which puts it in competition with Mirum.
Merck &
MRK
Mkt Cap318.6B
Merck & Co., Inc. offers a variety of healthcare products and services, including treatments for liver diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap212.54B
AstraZeneca operates in multiple therapeutic areas, including liver diseases, directly competing with Mirum's product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap99.17B
Bristol Myers Squibb has a diverse portfolio in healthcare, including liver disease treatments, positioning it as a competitor to Mirum Pharmaceuticals.

Analyst Ratings

52.75$Average Price Target
The highest estimate is $72.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Show more...
CEO
Employees
264
Country
US
ISIN
US6047491013
WKN
000A2PM29

Listings